for the Period Ended 31 December 2023
Balance sheet | |
Additional notes | |
Balance sheet notes | |
Community Interest Report |
As at
Notes | 2023 | 2022 | |
---|---|---|---|
|
£ |
£ |
|
Current assets | |||
Debtors: | 3 |
|
|
Cash at bank and in hand: |
|
|
|
Total current assets: |
|
|
|
Creditors: amounts falling due within one year: | 4 |
(
|
(
|
Net current assets (liabilities): |
|
|
|
Total assets less current liabilities: |
|
|
|
Total net assets (liabilities): |
|
|
|
Members' funds | |||
Profit and loss account: |
|
|
|
Total members' funds: |
|
|
The notes form part of these financial statements
The directors have chosen not to file a copy of the company's profit and loss account.
This report was approved by the board of directors on
and signed on behalf of the board by:
Name:
Status: Director
The notes form part of these financial statements
for the Period Ended 31 December 2023
Basis of measurement and preparation
Turnover policy
Other accounting policies
for the Period Ended 31 December 2023
2023 | 2022 | |
---|---|---|
Average number of employees during the period |
|
|
for the Period Ended 31 December 2023
2023 | 2022 | |
---|---|---|
£ | £ | |
Trade debtors |
|
|
Prepayments and accrued income |
|
|
Other debtors |
|
|
Total |
|
|
for the Period Ended 31 December 2023
2023 | 2022 | |
---|---|---|
£ | £ | |
Trade creditors |
|
|
Taxation and social security |
|
|
Accruals and deferred income |
|
|
Total |
|
|
MS Service Development: In 2023 Transform MS CIC has been instrumental in the development and growth of an initiative called Transforming MS for all (TMSFA). TMSFA is an MS clinical community-led initiative seeking to improve clinical services, and related activities, supporting people with MS. It has been developed to solve challenges represented by 70 clinical centres across the whole UK and to develop ongoing consensus within the community around priority projects. Transform MS CIC hosts this initiative, providing support and the infrastructure needed to apply for and manage grants and deliver projects. Highlights for 2023 include. Launch of the TMSFA website (https://transformingmsforall.org/) which hosts resources and useful information for the MS community. Delivery of the TMSFA summit meeting: a national meeting for the TMSFA community held at the Kings Fund London with circa 80 people in attendance. Securing in excess of £100k of funding through application for, and management of grants, from commercial pharmaceutical companies to support the delivery of the programme of work linked to TMSFA priority projects. Transform MS CIC have also continued to support the development of the local South West MS network directly. We have continued to use our resources and contacts to raise funds to support a monthly Regional MS Clinical meeting that has improved accuracy of diagnosis and treatment decision making for people with MS across Devon and Cornwall. We also supported the commencement of a programme of webinars linked to a website and research community developed in partnership with the South West Peninsula Clinical Research Network. (https://sites.google.com/nihr.ac.uk/swp-ms-network/home). The first webinar was hosted on 21 November 2023 and had an audience of over 130 people. (https://sites.google.com/nihr.ac.uk/swp-ms-network/podcasts-and-events/webinar-multiple-sclerosis-research-in-focus) Community Benefits: Establishment of community, infrastructure and leverage of funding to support MS community projects focus on improving care and developing clinical services across the UK and locally. Promoting research and new information about MS research to a broader community to benefit people with MS and encourage development of a research focussed community. Measurement Consultancy: Transform MS continues to support projects to advance the understanding and quality of the measurement of health, primarily in the context of clinical research. Improved quality of measurement (our focus is on Patient Reported Outcome measures) helps support the collection of evidence required to develop and approve new treatments. The projects have seen the development and piloting of a new measure of Upper Limb Function in people with MS and projects to understand the impact of fatigue in people with MS and the suitability of measures intended to measure it. The learnings and opportunities from this work has been shared at various MS meetings and/or in academic publications. Community Benefits: Our goal is increased awareness of the value of high-quality measurement, developing knowledge and understanding of novel, modern approaches to data analysis in clinical studies. New insights and tools to support measurement of key symptom impacts in MS are required to improve effectiveness of clinical research. Scales Licensing: Transform MS commenced licensing activity of Patient Reported Outcome measures in 2023. These tools are used to provide important information on disease progression in people with Neurological Conditions. This information helps inform clinical trials of new treatments and clinical monitoring for targeting care. In 2023 Transform MS provided 8 licenses for large scale clinical trials of new treatments/interventions. In addition to commercial licensing Transform MS has also implemented a policy where projects which wish to use the outcome measures but are being delivered using public/rather than commercial funding either get a free license or a significant discount. In 2023 there were 3 licenses for clinical or academic projects issued on this basis. Community Benefits: Transform MS, through its licensing of Patient Reported Outcome measures, directly contributes to the advancement of knowledge relating to MS and the impact of treatments and interventions. MS Education and Research: Our team, including honorary staff members, have been involved in activities that help advance knowledge specific to MS clinical care. This includes participation in seminars/on-line meetings both in the UK and internationally, to talk about clinical services and research. At a local level, we have also supported delivery of a module focussed on MS care at the University of Plymouth and support a student project researching the impact on COVID-19 on the diagnosis and treatment of people with MS. Community Benefits: Helping advance the knowledge of people within the medical community on the latest developments and practices in MS care and research. Medical Reports: Provision of over 50 medical reports/documentation to support people with MS. Community Benefits: These reports provide important information for people with MS to evidence the impact of their MS and so represents a direct community benefit. Community Events/Centres: Transform MS has developed stronger relationships with the local MS society groups and two regional MS Centres. These groups have committed to promoting activities that Transform MS supports, through social media and newsletters, as well as contributing to projects. Transform MS also supported these organisations in the delivery of their activities through advice and guidance and financial support. This includes providing 50% of the funding to support the South Devon MS Society’s first face to face meeting since COVID. Community Benefits: Helping develop and support the local MS community through events and dissemination of information of value to people with MS in our local community.
The primary community stakeholders for Transform MS CIC are people with MS and the clinical teams that support them. In our broader stakeholder network we work with Pharmaceutical companies and research teams that are focussed on research linked to MS and Measurement Science in healthcare. In the activities of Transform MS CIC, listed in the previous section, people with MS and the MS clinical teams are directly involved in many of them and as a result directly inform the delivery of our projects and activities. The TMSFA initiative – was launched following interviews with over 70 MS clinical centres. Following this, a report was produced that was endorsed by those centres that proposed the development of Transforming MS for all to help address some of these challenges. In 2023 a national meeting was held in London, attended by circa 80 people from all four home nations of the UK. This meeting decided on the focus for the TMSFA initiative for the year ahead. The TMSFA website also hosts a discussion forum where ideas and suggestions are received for the focus of future projects. The Research website referenced was designed by community input – people with MS, clinicians and researchers. It has a section which encourages the community to highlight areas that would benefit from research. Additionally at the webinar referenced in the previous section people were asked to submit questions that were important for them in terms of MS research. The webinar then covered these areas with any not addressed responded to in a post event document. During collaborative work to support the Regional MS Clinical meeting and efforts to develop the South West MS research community Transform MS has worked closely with the 5 NHS hospital trusts in Devon and Cornwall, their MS Consultants and Specialist Nurses as well as the Health Innovation South West. These groups form part of the clinical community that are an important partner in delivering service improvements that benefit future outcomes for people with MS. As outlined above, at this stage of its development, community consultation has remained largely at the project level. As the company grows further in 2024 it is developing its partnership and engagement model and within this will seek to identify additional ways to deliver its social purpose and as part of that increased formal consultation with community partners will take place.
No remuneration was received
No transfer of assets other than for full consideration
This report was approved by the board of directors on
13 September 2024
And signed on behalf of the board by:
Name: Jerry Clough
Status: Director